This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Alphabet, Abbott, & Charles Schwab
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Abbott Laboratories (ABT) and The Charles Schwab Corporation (SCHW).
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $121.76, moving -0.56% from the previous trading session.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.48, marking a +1.7% move from the previous day.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $118.39, marking a +1.96% move from the previous day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $120.36, marking a +1.85% move from the previous day.
Abbott (ABT) Down 1.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Stock Moves -0.22%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $117.25, moving -0.22% from the previous trading session.
Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
by Zacks Equity Research
Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.
3 Medical Products Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
by Zacks Equity Research
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN
by Debanjana Dey
The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.
Top Analyst Reports for Apple, Tesla & Johnson & Johnson
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Tesla, Inc. (TSLA), and Johnson & Johnson (JNJ).
HCA Healthcare's (HCA) Q4 Earnings Miss Mark, Improve Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) Q4 results reflect higher expenses, partly offset by better revenues owing to improved patient volumes.
Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Abbott (ABT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 11.86% and 8.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
S&P 500 Corrects Ahead Of Fed Meeting: Let's Check The Technicals
by Daniel Laboe
It's been a crazy start to what is expected to be the most pivotal week of Q1 market action.
S&P 500 Enters Correction Territory As Investors De-Risk Ahead of Fed Meeting & Big Tech Earnings
by Daniel Laboe
Bears have taken market control but the Fed's policy decision coupled with big tech earnings could reverse this negative narrative
Is a Surprise Coming for Abbott (ABT) This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings
by Zacks Equity Research
With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.